SR 4: REQUESTING THE AUDITOR TO ASSESS BOTH THE SOCIAL AND FINANCIAL EFFECTS OF PROPOSED MANDATED HEALTH INSURANCE COVERAGE FOR A PERCENTAGE OF THE COSTS OF INTRAVENOUS KETAMINE THERAPY TO TREAT DEPRESSION.
- Session Year: 2025-2026
- House: Senate
Current Status:
In Progress
(2025-03-24: The committee on HHS deferred the measure.)
Introduced
First Committee Review
First Chamber
Second Committee Review
Second Chamber
Final Decking
Enacted
Version:
REQUESTING THE AUDITOR TO ASSESS BOTH THE SOCIAL AND FINANCIAL EFFECTS OF PROPOSED MANDATED HEALTH INSURANCE COVERAGE FOR A PERCENTAGE OF THE COSTS OF INTRAVENOUS KETAMINE THERAPY TO TREAT DEPRESSION.
Discussed in Hearing
42SECMar 24, 2025